LRRN4CL

Across TCGA pan-cancer cohorts, LRRN4CL RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of LRRN4CL’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where LRRN4CL RNA is repressed in tumor relative to normal tissue. In most cancer types LRRN4CL is over-expressed in tumor, although a few such as BLCA and THCA show the opposite, repressed pattern.

BLCA, THCA, and COAD are the cancer types where LRRN4CL tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LRRN4CL RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	III,IV	−3.095	<.001	11	view →
THCA	Male	II,III,IV	−2.265	<.001	11	view →
COAD	Male	All	−1.349	<.001	11	view →
HNSC	Male	IV	−2.051	<.001	8	view →
KIRC	Male	II,III,IV	+1.114	<.001	8	view →
LUSC	Female	All	−1.175	<.001	7	view →
STAD	All	All	−1.159	<.001	7	view →
KICH	Female	All	−1.062	<.001	7	view →
UCEC	All	III,IV	−3.882	<.001	6	view →
BRCA	All	II,III,IV	−2.883	<.001	6	view →
LUAD	All	All	−0.588	<.001	5	view →
LIHC	All	All	+0.145	.005	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

LRRN4CL–BLCA

Open the BLCA breakdown →